secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arch Therapeutics, Inc. (—)
CIK:        0001537561
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0001437749-24-006302
Event type: debt
Sentiment:  negative
Materiality: 0.60
Item codes: 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Arch Therapeutics receives $250K advance from SPA purchaser; warrants may replace repayment if closing delayed
--------------------------------------------------------------------------------

- Advancing Purchaser provided $250,000 as partial prepayment under November 2023 SPA.
- If closing fails by March 31, 2024, purchaser can take pre-funded warrants for 484,966 shares and common warrants for 484,966 shares instead of repayment.
- If Nasdaq listing not approved by March 31, Company must issue additional 121,241 pre-funded and common warrants (25% increase) by April 2.
- Warrant exercise price referenced as $0.5155 per pre-funded warrant; total potential dilution exceeds 1 million shares.
- Advance triggers new direct financial obligation under Item 2.03 disclosure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1537561/000143774924006302/0001437749-24-006302-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1537561/000143774924006302/arch20240229_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-006302

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer